Quarterly report pursuant to Section 13 or 15(d)

NON CONTROLLING INTEREST (Tables)

NON CONTROLLING INTEREST (Tables)

9 Months Ended

Sep. 30, 2023

NON CONTROLLING INTEREST

Schedule of net loss attributable to non-controlling interest

		BioCorRx Pharmaceuticals, Inc.				Joseph DeSanto MD
Net loss		$	(2,397	)		$	(1,395	)
Average Non-controlling interest percentage of profit/losses			24.2	%			35.0	%
Net loss attributable to the non-controlling interest		$	(580	)		$	(488	)

		BioCorRx Pharmaceuticals, Inc.
Net loss		$	(7,802	)
Average Non-controlling interest percentage of profit/losses			24.2	%
Net loss attributable to the non-controlling interest		$	(1,888	)

		BioCorRx Pharmaceuticals, Inc.				Joseph DeSanto MD
Net loss		$	(5,692	)		$	(4,945	)
Average Non-controlling interest percentage of profit/losses			24.2	%			35.0	%
Net loss attributable to the non-controlling interest		$	(1,378	)		$	(1,730	)

		BioCorRx Pharmaceuticals, Inc.
Net loss		$	(17,335	)
Average Non-controlling interest percentage of profit/losses			24.2	%
Net loss attributable to the non-controlling interest		$	(4,195	)

Schedule of changes in non controlling interest

Balance, December 31, 2022		$	(125,257	)
Net loss attributable to the non-controlling interest			(3,108	)
Balance, September 30, 2023		$	(128,365	)

Balance, December 31, 2021		$	(117,838	)
Net loss attributable to the non-controlling interest			(4,195	)
Balance, September 30, 2022		$	(122,033	)